Results of IVGTT and euglycemic clamp studies performed during the early third trimester and 15 months postpartum in women who remained nonpreeclamptic and those who developed preeclampsia at delivery
| . | Antepartum . | . | . | Postpartum . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | Non-preeclamptic . | Preeclampsia . | P . | Non-preeclamptic . | Preeclampsia . | P . | ||||
| n | 121 (80.7%) | 29 (19.3%) | 70 (78.4%) | 19 (21.6%) | ||||||
| IVGTT | ||||||||||
| SI[min−1 · (μU/ml)−1]104 | 0.63 ± 0.49 | 0.64 ± 0.37 | 0.72 | 1.49 ± 1.06 | 1.43 ± 0.92 | 0.53 | ||||
| Glucose effectiveness (min−1 · 102) | 0.019 ± 0.004 | 0.020 ± 0.004 | 0.10 | 0.016 ± 0.004 | 0.016 ± 0.004 | 0.78 | ||||
| AIRg (μU · ml−1 · min) | 923.7 ± 1,098.8 | 928.3 ± 637.9 | 0.43 | 550.9 ± 479.0 | 502.0 ± 472.2 | 0.21 | ||||
| Disposition index | 517.4 ± 584.3 | 547.3 ± 428.3 | 0.53 | 772.5 ± 630.2 | 705.2 ± 587.8 | 0.63 | ||||
| Euglycemic clamp study | ||||||||||
| Basal glucose clamp | ||||||||||
| Plasma glucose (mmol/l) | 5.39 ± 0.50 | 5.42 ± 0.60 | 0.81 | 6.19 ± 1.52 | 6.06 ± 1.16 | 0.73 | ||||
| Plasma insulin (μU/ml) | 23.4 ± 9.0 | 29.6 ± 26.1 | 0.23 | 20.8 ± 8.1 | 21.1 ± 7.8 | 0.82 | ||||
| Plasma FFA (μmol/ml) | 435.9 ± 111.7 | 476.9 ± 143.7 | 0.13 | — | — | |||||
| Plasma C-peptide (ng/ml) | 2.26 ± 0.50 | 2.37 ± 0.65 | 0.30 | — | — | |||||
| Plasma glucagon (pg/dl) | 37.5 ± 12.1 | 35.6 ± 9.9 | — | — | ||||||
| Glucose production (mmol · min–1 · m2) | 0.494 ± 0.72 | 0.508 ± 0.075 | 0.38 | 0.381 ± 0.065 | 0.382 ± 0.045 | 0.81 | ||||
| Glucose clearance (ml · min–1 · m2) | 0.097 ± 0.011 | 0.096 ± 0.012 | 0.69 | 0.068 ± 0.013 | 0.068 ± 0.11 | 0.89 | ||||
| Steady-state glucose clamp | ||||||||||
| Plasma glucose (mmol/l) | 4.81 ± 0.11 | 4.81 ± 0.13 | 0.77 | 4.80 ± 0.14 | 4.85 ± 0.32 | 0.80 | ||||
| Plasma insulin (μU/ml) | 101.6 ± 23.1 | 107.0 ± 31.0 | 0.37 | 89.9 ± 20.9 | 90.3 ± 18.5 | 0.82 | ||||
| Plasma FFA (μmol/ml) | 180.9 ± 70.3 | 181.1 ± 71.5 | 0.99 | — | — | |||||
| Plasma C-peptide (ng/ml) | 1.48 ± 0.56 | 1.52 ± 0.71 | 0.79 | — | — | |||||
| Glucose production (mmol · min–1 · m2) | 0.161 ± 0.060 | 0.180 ± 0.090 | 0.32 | 0.122 ± 0.067 | 0.149 ± 0.061 | 0.29 | ||||
| Glucose clearance (ml · min–1 · m2) | 0.586 ± 0.137 | 0.555 ± 0.71 | 0.64 | 0.172 ± 0.042 | 0.171 ± 0.064 | 0.93 | ||||
| . | Antepartum . | . | . | Postpartum . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | Non-preeclamptic . | Preeclampsia . | P . | Non-preeclamptic . | Preeclampsia . | P . | ||||
| n | 121 (80.7%) | 29 (19.3%) | 70 (78.4%) | 19 (21.6%) | ||||||
| IVGTT | ||||||||||
| SI[min−1 · (μU/ml)−1]104 | 0.63 ± 0.49 | 0.64 ± 0.37 | 0.72 | 1.49 ± 1.06 | 1.43 ± 0.92 | 0.53 | ||||
| Glucose effectiveness (min−1 · 102) | 0.019 ± 0.004 | 0.020 ± 0.004 | 0.10 | 0.016 ± 0.004 | 0.016 ± 0.004 | 0.78 | ||||
| AIRg (μU · ml−1 · min) | 923.7 ± 1,098.8 | 928.3 ± 637.9 | 0.43 | 550.9 ± 479.0 | 502.0 ± 472.2 | 0.21 | ||||
| Disposition index | 517.4 ± 584.3 | 547.3 ± 428.3 | 0.53 | 772.5 ± 630.2 | 705.2 ± 587.8 | 0.63 | ||||
| Euglycemic clamp study | ||||||||||
| Basal glucose clamp | ||||||||||
| Plasma glucose (mmol/l) | 5.39 ± 0.50 | 5.42 ± 0.60 | 0.81 | 6.19 ± 1.52 | 6.06 ± 1.16 | 0.73 | ||||
| Plasma insulin (μU/ml) | 23.4 ± 9.0 | 29.6 ± 26.1 | 0.23 | 20.8 ± 8.1 | 21.1 ± 7.8 | 0.82 | ||||
| Plasma FFA (μmol/ml) | 435.9 ± 111.7 | 476.9 ± 143.7 | 0.13 | — | — | |||||
| Plasma C-peptide (ng/ml) | 2.26 ± 0.50 | 2.37 ± 0.65 | 0.30 | — | — | |||||
| Plasma glucagon (pg/dl) | 37.5 ± 12.1 | 35.6 ± 9.9 | — | — | ||||||
| Glucose production (mmol · min–1 · m2) | 0.494 ± 0.72 | 0.508 ± 0.075 | 0.38 | 0.381 ± 0.065 | 0.382 ± 0.045 | 0.81 | ||||
| Glucose clearance (ml · min–1 · m2) | 0.097 ± 0.011 | 0.096 ± 0.012 | 0.69 | 0.068 ± 0.013 | 0.068 ± 0.11 | 0.89 | ||||
| Steady-state glucose clamp | ||||||||||
| Plasma glucose (mmol/l) | 4.81 ± 0.11 | 4.81 ± 0.13 | 0.77 | 4.80 ± 0.14 | 4.85 ± 0.32 | 0.80 | ||||
| Plasma insulin (μU/ml) | 101.6 ± 23.1 | 107.0 ± 31.0 | 0.37 | 89.9 ± 20.9 | 90.3 ± 18.5 | 0.82 | ||||
| Plasma FFA (μmol/ml) | 180.9 ± 70.3 | 181.1 ± 71.5 | 0.99 | — | — | |||||
| Plasma C-peptide (ng/ml) | 1.48 ± 0.56 | 1.52 ± 0.71 | 0.79 | — | — | |||||
| Glucose production (mmol · min–1 · m2) | 0.161 ± 0.060 | 0.180 ± 0.090 | 0.32 | 0.122 ± 0.067 | 0.149 ± 0.061 | 0.29 | ||||
| Glucose clearance (ml · min–1 · m2) | 0.586 ± 0.137 | 0.555 ± 0.71 | 0.64 | 0.172 ± 0.042 | 0.171 ± 0.064 | 0.93 | ||||
Data are means ± SD. Antepartum data were obtained in the early third trimester prior to the development of preeclampsia and postpartum data at a mean of 15 months after delivery. Data for the basal clamp were obtained during the last 90 min of a 180-min basal tracer infusion, before insulin infusion; those for the steady-state glucose clamp were obtained during the last 30 min of insulin infusion. Postpartum measures of FFA, C-peptide, and glucagons were not evaluated. There were no significant differences between nonpreeclamptic and preeclampsia metabolic parameters measured in antepartum or postpartum tests.